Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 96, Issue 2, Pages 162-165Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2014.113
Keywords
-
Categories
Funding
- Abbvie
- Abbott Molecular
- Achillion
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cenetron
- DDL Diagnostics
- Genentech
- Gilead Sciences
- GlaxoSmithKline
- Idenix
- Janssen
- Merck Laboratories
- Monogram
- Novartis
- PPD
- Quest
- Quintiles
- Roche Molecular Diagnostics
- Vertex
Ask authors/readers for more resources
Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's(1) HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available